Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
Date:12/23/2010

SAN FRANCISCO, Dec. 23, 2010 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTC Bulletin Board: PRWP) ("the Company") and maintains its twelve month target price to $2.10. Ross Silver, Principal Analyst at Vista Partners, stated, "DAVANAT®, the Company's lead product candidate, could potentially enhance the efficacy of already approved oncology drugs, such as Avastin®, while also reducing the side effect profile of these drugs. By doing so, patients potentially will live longer and live better and the cost of treatment could be reduced significantly." Mr. Silver goes on to state, "The Company has stated that development of its GR series of compounds, novel carbohydrate compounds intended to treat liver fibrosis, will commence in January 2011. The Company recently entered into a research agreement with the premier liver disease expert in the U.S., Dr. Scott Freidman, at Mt. Sinai Hospital in New York.  Liver disease is considerable and according to the American Liver Foundation, more than 25 million Americans are or have been afflicted with liver and biliary diseases."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:

Ross Silver, 877.215.4813 or info@vistapglobal.com




'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
3. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
4. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
5. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
6. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
7. Watson Confirms EVISTA(R) Patent Challenge
8. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
9. Biovista Inc. Named Top Innovator in Life Sciences
10. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the launch ... address the nutritional needs of recovery for a variety of clinical conditions. Founded in ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)...  Deerfield announced today it led the $44.5 ... Graybug Vision is an early stage pharmaceutical company ... for ocular diseases including wet age-related macular degeneration ... developed at Johns Hopkins University and has been ... Graybug Vision is developing ophthalmology products enabling ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... Trinity Health today launched its inaugural ... aimed at improving care and reducing readmission rates for patients who are dually ... Health is to drive innovation that transforms our ministry and our industry to ...
(Date:5/4/2016)... SCOTTSDALE, AZ (PRWEB) , ... May 04, 2016 ... ... 2016 Annual Technology & Business Conference. The conference opened on Tuesday with Frank ... panel discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model ...
(Date:5/4/2016)... ... ... Level 10 Head Over Heels Athletic Arts’ gymnast Alessandra Brovedani -- who goes ... fall of 2019. , After a handful of college visits, the Berkeley High ... her connection with the coaching staff and the excitement surrounding Wildcat Athletics. , “What ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... therapy products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... hip replacement patients. The plush design enhances comfort and enables the patient to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , “I’m excited for our eighth summer here ...
Breaking Medicine News(10 mins):